S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
NASDAQ:INZY

Inozyme Pharma Stock Forecast, Price & News

$13.10
-0.26 (-1.95 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.35
$13.91
50-Day Range
$11.48
$19.40
52-Week Range
$11.12
$29.46
Volume33,893 shs
Average Volume66,849 shs
Market Capitalization$309.97 million
P/E RatioN/A
Dividend YieldN/A
Beta2.47
30 days | 90 days | 365 days | Advanced Chart
Receive INZY News and Ratings via Email

Sign-up to receive the latest news and ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter.


Inozyme Pharma logo

About Inozyme Pharma

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.50 out of 5 stars

Medical Sector

1042nd out of 1,351 stocks

Pharmaceutical Preparations Industry

507th out of 664 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Inozyme Pharma (NASDAQ:INZY) Frequently Asked Questions

What stocks does MarketBeat like better than Inozyme Pharma?

Wall Street analysts have given Inozyme Pharma a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Inozyme Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Inozyme Pharma's next earnings date?

Inozyme Pharma is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Inozyme Pharma
.

How were Inozyme Pharma's earnings last quarter?

Inozyme Pharma, Inc. (NASDAQ:INZY) released its quarterly earnings data on Wednesday, August, 11th. The company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.57) by $0.04.
View Inozyme Pharma's earnings history
.

Who are Inozyme Pharma's key executives?

Inozyme Pharma's management team includes the following people:
  • Mr. Axel Bolte, Pres, CEO & Director (Age 49, Pay $771.4k) (LinkedIn Profile)
  • Mr. Henric Bjorn Bjarke, Sr. VP & COO (Age 54, Pay $576.88k)
  • Mr. Stephen J. DiPalma M.B.A., Interim Chief Financial Officer (Age 62)
  • Mr. Steven J. Jungles, Sr. VP & Chief Technical Operations Officer (Age 56)
  • Dr. Yves Sabbagh Ph.D., Chairman of Scientific Advisory Board, Sr. VP & Chief Scientific Officer
  • Mr. Brian Luque, Director of Investor Relations
  • Dr. Kevin B. Johnson M.B.A., Ph.D., MBA., Sr. VP of Regulatory Affairs, Quality & Product Devel.
  • Dr. Deborah Wenkert M.D., Sr. VP & Chief Medical Officer (Age 62)

What other stocks do shareholders of Inozyme Pharma own?

When did Inozyme Pharma IPO?

(INZY) raised $75 million in an initial public offering on Friday, July 24th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Inozyme Pharma's stock symbol?

Inozyme Pharma trades on the NASDAQ under the ticker symbol "INZY."

Who are Inozyme Pharma's major shareholders?

Inozyme Pharma's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (3.83%), Vanguard Group Inc. (1.43%), Burrage Capital Management LLC (1.02%), Geode Capital Management LLC (0.77%), Citadel Advisors LLC (0.72%) and State Street Corp (0.72%). Company insiders that own Inozyme Pharma stock include Axel Bolte, Holdings A/S Novo, Longitude Capital Partners Iii and Robert Lorne Hopfner.
View institutional ownership trends for Inozyme Pharma
.

Which institutional investors are selling Inozyme Pharma stock?

INZY stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Citadel Advisors LLC, Marshall Wace LLP, Marshall Wace LLP, Bank of America Corp DE, Vanguard Group Inc., JPMorgan Chase & Co., and Goldman Sachs Group Inc.. Company insiders that have sold Inozyme Pharma company stock in the last year include Axel Bolte, and Holdings A/S Novo.
View insider buying and selling activity for Inozyme Pharma
or view top insider-selling stocks.

Which institutional investors are buying Inozyme Pharma stock?

INZY stock was acquired by a variety of institutional investors in the last quarter, including Burrage Capital Management LLC, BlackRock Inc., State Street Corp, Geode Capital Management LLC, Nuveen Asset Management LLC, Morgan Stanley, Morgan Stanley, and Bank of New York Mellon Corp. Company insiders that have bought Inozyme Pharma stock in the last two years include Longitude Capital Partners Iii, and Robert Lorne Hopfner.
View insider buying and selling activity for Inozyme Pharma
or or view top insider-buying stocks.

How do I buy shares of Inozyme Pharma?

Shares of INZY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inozyme Pharma's stock price today?

One share of INZY stock can currently be purchased for approximately $13.10.

How much money does Inozyme Pharma make?

Inozyme Pharma has a market capitalization of $309.97 million. The company earns $-56,420,000.00 in net income (profit) each year or ($5.11) on an earnings per share basis.

How many employees does Inozyme Pharma have?

Inozyme Pharma employs 38 workers across the globe.

What is Inozyme Pharma's official website?

The official website for Inozyme Pharma is www.inozyme.com.

How can I contact Inozyme Pharma?

The company can be reached via phone at 857-330-4340 or via email at [email protected].


This page was last updated on 9/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.